Sunovion Pharmaceuticals has acknowledged that its NDA for its chronic obstructive pulmonary disease (COPD) treatment candidate SUN-101/eFlow ® (glycopyrrolate) has been rejected by the FDA. The ...
SAN DIEGO, May 16, 2012 /PRNewswire via COMTEX/ -- Elevation Pharmaceuticals, Inc., a pharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, ...
St. Mark's United Methodist Church will host "COPD 101" from 9-11 a.m. Saturday at the church, 1431 W. Magee Road. The workshop is free and open to the public. Chronic obstructive pulmonary disease ...
Having the ability to take a nice deep breath is something some of us may take for granted. However, for the 12 million adults in the United States diagnosed with Chronic Obstructive Pulmonary Disease ...
VIENNA, Sept. 3, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study – a Phase 2b study evaluating EP-101 in patients with ...
SUN-101 (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator delivered via the innovative, proprietary investigational eFlow ® nebulizer closed system for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results